Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 1201 - 1300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1201 | 24928060 |
JP |
52 | |
Malignant pleural effusion, Pericarditis, Malignant neoplasm progression, |
||||
DURVALUMAB, TREMELIMUMAB, CISPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 1202 | 24928160 |
GB |
2 | |
Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, CYTARABINE, |
||||
| 1203 | 24928231 |
GB |
1 | |
Death, Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, |
||||
| 1204 | 24928343 |
JP |
1 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 1205 | 24928829 |
RU |
62 | 2 |
Thrombocytopenia, Anaemia, Metastases to bone, Malignant neoplasm progression, Inappropriate schedule of product administration, |
||||
RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, ZOLEDRONIC ACID, FULVESTRANT, |
||||
| 1206 | 24928900 |
US |
2 | |
Malignant neoplasm progression, |
||||
RUCAPARIB, RUCAPARIB, |
||||
| 1207 | 24928906 |
US |
2 | |
Malignant neoplasm progression, Carbohydrate antigen 125 increased, |
||||
RUCAPARIB, |
||||
| 1208 | 24928912 |
US |
2 | |
Malignant neoplasm progression, |
||||
RUCAPARIB, |
||||
| 1209 | 24928956 |
US |
40 | 2 |
Chromaturia, Intra-abdominal fluid collection, Malignant neoplasm progression, Haemoglobin decreased, |
||||
PEMBROLIZUMAB, |
||||
| 1210 | 24929175 |
JP |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 1211 | 24929205 |
RS |
46 | 1 |
Malignant neoplasm progression, Metastases to lymph nodes, Lymphadenopathy, |
||||
PEMBROLIZUMAB, |
||||
| 1212 | 24929223 |
CA |
71 | 2 |
Abdominal distension, Abdominal pain, Abdominal pain, Abdominal pain, Abdominal pain upper, Alopecia, Back pain, Back pain, Diarrhoea, Eructation, Faeces discoloured, Fall, Fatigue, Flatulence, Frequent bowel movements, Headache, Injection site bruising, Injection site mass, Injection site pain, Injection site pain, Insomnia, Loss of personal independence in daily activities, Malaise, Malignant neoplasm progression, Musculoskeletal chest pain, Osteoporosis, Pain in extremity, Pelvic fracture, Weight decreased, Therapeutic response shortened, Off label use, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LANREOTIDE ACETATE, LEMBOREXANT, DOXYLAMINE SUCCINATE, IVERMECTIN, MELATONIN, ERGOCALCIFEROL, |
||||
| 1213 | 24930036 |
DE |
||
Death, Pancytopenia, Malignant neoplasm progression, |
||||
CARBOPLATIN, PEMBROLIZUMAB, PEMETREXED DISODIUM, PEMETREXED, |
||||
| 1214 | 24930407 |
US |
71 | 2 |
Renal cell carcinoma, Malignant neoplasm progression, Drug ineffective, |
||||
EVEROLIMUS, |
||||
| 1215 | 24930510 |
JP |
||
Transformation to acute myeloid leukaemia, Malignant neoplasm progression, Myelofibrosis, |
||||
RUXOLITINIB, |
||||
| 1216 | 24932526 |
CO |
76 | 1 |
Dysphagia, Fatigue, Diarrhoea, Malignant neoplasm progression, Visual impairment, Feeling cold, Nail discolouration, Body height decreased, Speech disorder, Gait disturbance, Dysphagia, Stomatitis, Oral mucosal erythema, Abdominal pain upper, Constipation, Diarrhoea, Epistaxis, Dizziness, Abdominal discomfort, Fatigue, Fatigue, Stomatitis, Weight decreased, |
||||
CABOZANTINIB, CABOZANTINIB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 1217 | 24932924 |
FR |
73 | 2 |
Malignant neoplasm progression, Cholestasis, Hepatic cytolysis, Jaundice, Condition aggravated, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, DOSTARLIMAB, DOSTARLIMAB, |
||||
| 1218 | 24936357 |
70 | 2 | |
Malignant neoplasm progression, Metastatic neoplasm, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
| 1219 | 24918895 |
US |
66 | |
Malignant neoplasm progression, Off label use, |
||||
IPILIMUMAB, NIVOLUMAB, |
||||
| 1220 | 24919185 |
DE |
||
Metastases to liver, Lung neoplasm malignant, Metastases to central nervous system, Malignant neoplasm progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, NINTEDANIB, NINTEDANIB, |
||||
| 1221 | 24919940 |
GB |
2 | |
Malignant neoplasm progression, Fatigue, Neutropenia, |
||||
CARBOPLATIN, ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 1222 | 24920038 |
JP |
79 | 1 |
Malignant neoplasm progression, Sepsis, Eastern Cooperative Oncology Group performance status worsened, Rash, Urinary tract infection, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, GEMCITABINE HYDROCHLORIDE, CISPLATIN, |
||||
| 1223 | 24920500 |
JP |
2 | |
Malignant neoplasm progression, Ascites, Hepatic function abnormal, |
||||
PEMBROLIZUMAB, |
||||
| 1224 | 24921602 |
ES |
59 | 2 |
Malignant neoplasm progression, Abdominal pain, Osteoarthritis, Diarrhoea, Fatigue, Weight increased, |
||||
LETROZOLE, LETROZOLE TABLETS, ABEMACICLIB, |
||||
| 1225 | 24922384 |
JP |
8 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, AXITINIB, |
||||
| 1226 | 24922494 |
US |
||
Malignant neoplasm progression, |
||||
ELACESTRANT, |
||||
| 1227 | 24923115 |
JP |
||
Interstitial lung disease, Malignant neoplasm progression, |
||||
OLAPARIB, OLAPARIB, |
||||
| 1228 | 24923954 |
CO |
2 | |
Pain in extremity, Metastases to bone, Metastases to spine, Metastasis, Vomiting, Syncope, Liver function test increased, Dizziness, Malignant neoplasm progression, Hormone receptor positive HER2 negative breast cancer, Laboratory test abnormal, Anxiety, Insomnia, Pyrexia, Bone lesion, Chest scan abnormal, Therapeutic product effect incomplete, Arthralgia, Pain in extremity, Bone pain, Gait disturbance, |
||||
RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, LETROZOLE, LETROZOLE, |
||||
| 1229 | 24924079 |
JP |
75 | 1 |
Malignant neoplasm progression, Immune-mediated adverse reaction, Diarrhoea, |
||||
PEMBROLIZUMAB, |
||||
| 1230 | 24924096 |
US |
2 | 2 |
Drug ineffective for unapproved indication, Metastasis, Malignant neoplasm progression, |
||||
THALIDOMIDE, THALIDOMIDE, CLONAZEPAM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, FENOFIBRATE, CELECOXIB, ERGOCALCIFEROL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 1231 | 24924101 |
JP |
54 | 1 |
Liver disorder, Malignant neoplasm progression, Immune-mediated dermatitis, |
||||
NIVOLUMAB, NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 1232 | 24924141 |
US |
1 | |
Chronic myeloid leukaemia, Malignant neoplasm progression, Therapy non-responder, |
||||
ASCIMINIB, |
||||
| 1233 | 24924246 |
GB |
57 | 1 |
Off label use, White blood cell count decreased, Contraindicated product administered, Neutrophil count decreased, Malignant neoplasm progression, Malignant neoplasm progression, |
||||
CETUXIMAB, CLOZAPINE, CLOZAPINE, FLUOROURACIL, FOLIC ACID, |
||||
| 1234 | 24924495 |
CA |
75 | 1 |
Malignant neoplasm progression, |
||||
UPADACITINIB, |
||||
| 1235 | 24925612 |
US |
||
Multiple organ dysfunction syndrome, Sepsis, Drug ineffective, Malignant neoplasm progression, |
||||
DOXORUBICIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, TRABECTEDIN, METHYLPREDNISOLONE, METHYLPREDNISOLONE, |
||||
| 1236 | 24927661 |
58 | 2 | |
Therapy interrupted, Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 1237 | 24914314 |
CA |
2 | |
Malignant neoplasm progression, |
||||
UPADACITINIB, |
||||
| 1238 | 24914448 |
JP |
6 | 2 |
Malignant neoplasm progression, Ileus, Nausea, |
||||
ZOLBETUXIMAB, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL, OXALIPLATIN, OXALIPLATIN, NIVOLUMAB, |
||||
| 1239 | 24914465 |
JP |
35 | 2 |
Malignant neoplasm progression, Hepatic function abnormal, |
||||
PEMBROLIZUMAB, |
||||
| 1240 | 24914850 |
JP |
62 | 2 |
Cardiac failure congestive, Malignant neoplasm progression, Hyperthyroidism, Adverse reaction, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 1241 | 24915080 |
FR |
63 | 2 |
Malignant neoplasm progression, Neutropenia, Thrombocytopenia, |
||||
PACLITAXEL, PACLITAXEL, PACLITAXEL, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, DOSTARLIMAB, |
||||
| 1242 | 24915090 |
CA |
82 | 2 |
Diffuse large B-cell lymphoma, Malignant neoplasm progression, Therapy partial responder, |
||||
VINCRISTINE SULFATE, VINCRISTINE SULFATE, LENALIDOMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, EZETIMIBE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MIRABEGRON, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, PREDNISONE, PREDNISONE, |
||||
| 1243 | 24916303 |
EG |
2 | |
Malignant neoplasm progression, Recurrent cancer, |
||||
PEMBROLIZUMAB, |
||||
| 1244 | 24916730 |
US |
||
Breast cancer metastatic, Malignant neoplasm progression, |
||||
ELACESTRANT, |
||||
| 1245 | 24916812 |
NZ |
||
Malignant neoplasm progression, |
||||
NIRAPARIB, |
||||
| 1246 | 24917862 |
JP |
||
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL, |
||||
| 1247 | 24917878 |
JP |
58 | 2 |
Death, Gait inability, Eastern Cooperative Oncology Group performance status worsened, Malignant neoplasm progression, Pyrexia, Pain, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, |
||||
| 1248 | 24917978 |
BE |
67 | |
Myelodysplastic syndrome, Acute myeloid leukaemia, Malignant neoplasm progression, Metastases to liver, |
||||
OLAPARIB, |
||||
| 1249 | 24918044 |
JP |
72 | 1 |
Adrenocorticotropic hormone deficiency, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 1250 | 24918542 |
US |
72 | 1 |
Diarrhoea, Malignant neoplasm progression, Pleural effusion, |
||||
DASATINIB, |
||||
| 1251 | 24921639 |
64 | 1 | |
Malignant neoplasm progression, |
||||
TEMOZOLOMIDE, |
||||
| 1252 | 24913900 |
DE |
40 | 1 |
Cardiomyopathy, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 1253 | 24913482 |
JP |
75 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 1254 | 24913488 |
AU |
1 | |
Malignant neoplasm progression, Pneumonitis, |
||||
PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 1255 | 24913499 |
JP |
70 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL, |
||||
| 1256 | 24913504 |
JP |
74 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL, |
||||
| 1257 | 24913522 |
AU |
1 | |
Malignant neoplasm progression, Pneumonitis, |
||||
PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 1258 | 24913523 |
AU |
1 | |
Malignant neoplasm progression, Pneumonitis, |
||||
PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 1259 | 24913525 |
JP |
75 | 1 |
Malignant neoplasm progression, Lymphangiosis carcinomatosa, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL, |
||||
| 1260 | 24913613 |
US |
2 | |
Malignant neoplasm progression, Decreased appetite, Dysphagia, Dysphonia, Diarrhoea, Constipation, |
||||
PEMBROLIZUMAB, AXITINIB, VITAMIN C, ERGOCALCIFEROL, |
||||
| 1261 | 24913640 |
HR |
73 | 1 |
Malignant neoplasm progression, Tumour necrosis, Therapy partial responder, Fatigue, Vertigo, Fatigue, Therapy partial responder, Excessive granulation tissue, Therapy cessation, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 1262 | 24913645 |
US |
75 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
PEMBROLIZUMAB, |
||||
| 1263 | 24907677 |
CA |
4 | 1 |
Malignant pleural effusion, Rash, Malignant neoplasm progression, Wheezing, Abdominal pain, Cough, Drug hypersensitivity, Face oedema, |
||||
ETOPOSIDE, IFOSFAMIDE, IFOSFAMIDE, |
||||
| 1264 | 24907859 |
JP |
9 | 2 |
Malignant neoplasm progression, Depressed level of consciousness, Disseminated intravascular coagulation, Disorientation, Lymphoedema, Infection, |
||||
PEMBROLIZUMAB, |
||||
| 1265 | 24907883 |
CA |
69 | 1 |
Portal hypertension, Aortic arteriosclerosis, Hepatic cancer stage IV, Hepatic cirrhosis, Hepatic steatosis, Malignant neoplasm progression, Metastases to spine, |
||||
ROSUVASTATIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BISOPROLOL FUMARATE, |
||||
| 1266 | 24908055 |
US |
16 | 2 |
Malignant neoplasm progression, Biliary obstruction, Infection, Drug ineffective, |
||||
CAPECITABINE, OXALIPLATIN, CETUXIMAB, VEMURAFENIB, |
||||
| 1267 | 24908204 |
CZ |
2 | |
Peritonitis, Large intestine perforation, Malignant neoplasm progression, Drug intolerance, Fatigue, Gastrointestinal disorder, Haematotoxicity, |
||||
BEVACIZUMAB, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, |
||||
| 1268 | 24908226 |
BY |
1 | |
Malignant neoplasm progression, Anaemia, |
||||
BEDAQUILINE FUMARATE, BEDAQUILINE FUMARATE, PRETOMANID, LINEZOLID, LINEZOLID, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN, |
||||
| 1269 | 24908417 |
US |
82 | 2 |
Malignant neoplasm progression, Dehydration, Stress, Anxiety, Nasopharyngitis, Diarrhoea, |
||||
ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ANASTROZOLE, ANASTROZOLE TABLETS, WARFARIN, |
||||
| 1270 | 24908929 |
DE |
||
Death, Malignant neoplasm progression, Pancytopenia, |
||||
CARBOPLATIN, PEMBROLIZUMAB, PEMETREXED DISODIUM, PEMETREXED, |
||||
| 1271 | 24908935 |
CA |
69 | 1 |
Aortic arteriosclerosis, Hepatic cancer stage IV, Hepatic cirrhosis, Hepatic steatosis, Malignant neoplasm progression, Metastases to spine, Portal hypertension, |
||||
DAPAGLIFLOZIN, ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BISOPROLOL FUMARATE, DAPAGLIFLOZIN, |
||||
| 1272 | 24908978 |
US |
58 | 2 |
Colitis, Central nervous system lesion, Malignant neoplasm progression, Drug intolerance, |
||||
INFLIXIMAB, BINIMETINIB, ENCORAFENIB, PROMETHAZINE, OXYCODONE, OXYCODONE, DICYCLOMINE HYDROCHLORIDE, LEVETIRACETAM, |
||||
| 1273 | 24909573 |
CA |
82 | 2 |
Arthralgia, Lymphopenia, Malignant neoplasm progression, Pancytopenia, C-reactive protein abnormal, Joint swelling, Musculoskeletal stiffness, Cytopenia, |
||||
METHOTREXATE, METHOTREXATE SODIUM, UPADACITINIB, TOFACITINIB, RITUXIMAB, |
||||
| 1274 | 24910108 |
US |
55 | 1 |
Non-small cell lung cancer stage IV, Malignant neoplasm progression, Metastases to central nervous system, EGFR gene mutation, Respiratory failure, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, CAPMATINIB, CAPMATINIB, OSIMERTINIB, OSIMERTINIB, ENCORAFENIB, ENCORAFENIB, BINIMETINIB, BINIMETINIB, |
||||
| 1275 | 24910688 |
JP |
56 | 1 |
Plasma cell myeloma, Malignant neoplasm progression, |
||||
ELRANATAMAB-BCMM, ELRANATAMAB-BCMM, ELRANATAMAB-BCMM, TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM, PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, MINOCYCLINE HYDROCHLORIDE, OXYCODONE, FEBUXOSTAT, FEBUXOSTAT TABLETS 40 MG, FEBUXOSTAT TABLETS 80 MG, |
||||
| 1276 | 24910873 |
US |
55 | 1 |
Malignant neoplasm progression, |
||||
LENVATINIB, PEMBROLIZUMAB, |
||||
| 1277 | 24910875 |
US |
68 | 1 |
Pulmonary histoplasmosis, Cryptococcosis, Malignant neoplasm progression, Drug ineffective, |
||||
LENALIDOMIDE, |
||||
| 1278 | 24911222 |
DE |
||
General physical health deterioration, Malignant neoplasm progression, Toxicity to various agents, Fatigue, Decreased appetite, Weight decreased, |
||||
CABOZANTINIB, TORSEMIDE, METHYLDOPA, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, LEVOTHYROXINE, LEVOTHYROXINE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, |
||||
| 1279 | 24911467 |
CN |
||
Metastases to bone, Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 1280 | 24911473 |
JP |
6 | |
Metastases to liver, Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 1281 | 24911476 |
CN |
49 | |
Malignant neoplasm progression, Metastases to lymph nodes, Metastases to pelvis, |
||||
OLAPARIB, |
||||
| 1282 | 24911856 |
JP |
37 | 2 |
Malignant neoplasm progression, |
||||
LENVATINIB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 1283 | 24911896 |
US |
64 | 2 |
Malignant neoplasm progression, Hair growth abnormal, |
||||
RIPRETINIB, RIPRETINIB, RIPRETINIB, |
||||
| 1284 | 24911908 |
US |
50 | 2 |
Infection, Abdominal pain upper, Back pain, Malignant neoplasm progression, Wound, Wound haemorrhage, |
||||
RIPRETINIB, RIPRETINIB, RIPRETINIB, |
||||
| 1285 | 24911974 |
CA |
2 | |
Malignant neoplasm progression, |
||||
LENVATINIB, PEMBROLIZUMAB, |
||||
| 1286 | 24912638 |
TH |
57 | 2 |
Breast cancer, Metastases to liver, Metastases to bone, Metastases to lung, Malignant neoplasm progression, Off label use, |
||||
RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 1287 | 24902367 |
DE |
27 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
CARBOPLATIN, PACLITAXEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PEMBROLIZUMAB, SACITUZUMAB GOVITECAN, |
||||
| 1288 | 24902950 |
ZA |
70 | |
Malignant neoplasm progression, |
||||
PREGABALIN, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ROSUVASTATIN, |
||||
| 1289 | 24903444 |
CN |
54 | 2 |
Drug intolerance, Malignant neoplasm progression, Drug ineffective for unapproved indication, |
||||
DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, IFOSFAMIDE, |
||||
| 1290 | 24903527 |
US |
||
Malignant neoplasm progression, Haemorrhage, |
||||
ACALABRUTINIB, APIXABAN, |
||||
| 1291 | 24903791 |
TW |
56 | 2 |
Osteoporosis, Back pain, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, Metastases to lung, Metastases to bone, |
||||
LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, RIBOCICLIB, FULVESTRANT, |
||||
| 1292 | 24904722 |
CA |
2 | |
Anaplastic thyroid cancer, BRAF gene mutation, PIK3CA-activated mutation, Malignant neoplasm progression, Rash, Off label use, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 1293 | 24905083 |
US |
80 | 2 |
Malignant neoplasm progression, Treatment failure, |
||||
PEMBROLIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, FERROUS SULFATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, SIMVASTATIN, |
||||
| 1294 | 24905144 |
2 | ||
Pancreatic carcinoma, Malignant neoplasm progression, |
||||
CAPECITABINE, |
||||
| 1295 | 24905578 |
CA |
2 | |
Arthralgia, Malignant neoplasm progression, Metastatic neoplasm, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 1296 | 24905858 |
MX |
67 | 2 |
Neoplasm progression, Breast cancer, Malignant neoplasm progression, Feeling abnormal, Gait disturbance, Movement disorder, Bone demineralisation, Ill-defined disorder, Retching, Dysstasia, Alopecia, Pruritus, Dry skin, Mass, Oedema, Skin fissures, Weight decreased, Discomfort, Malaise, Pain, Fatigue, Calcium deficiency, Constipation, Abdominal pain upper, Vomiting, Nausea, Decreased appetite, Diarrhoea, Drug ineffective, Inappropriate schedule of product administration, Product availability issue, |
||||
RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 1297 | 24905998 |
US |
2 | |
Metastases to bone, Neutropenia, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, |
||||
FULVESTRANT, RIBOCICLIB, DENOSUMAB, |
||||
| 1298 | 24906060 |
TW |
56 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
FULVESTRANT, RIBOCICLIB, |
||||
| 1299 | 24906185 |
JP |
75 | 1 |
Immune-mediated dermatitis, Gastric perforation, Malignant neoplasm progression, Tumour haemorrhage, Pneumonia, |
||||
IPILIMUMAB, IPILIMUMAB, IPILIMUMAB, IPILIMUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, |
||||
| 1300 | 24906407 |
BR |
47 | 2 |
Malignant neoplasm progression, Uterine disorder, |
||||
LENALIDOMIDE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28